Statistics for REGENXBIO (id:7855 RGNX)

Valuation metrics

Market cap

454.82M

Enterprise value

367.47M

Trailing P/E (ttm)

-1.59

Forward P/E

-8.50

PEG ratio

-8.50

Price/Sales (ttm)

5.39

Price/Book (mrq)

1.51

Enterprise Value/Revenue

4.36

Enterprise Value/EBITDA

-1.64

Overview

Shares outstanding

49.55M

Float

40.92M

Shares short

4.91M

% Held by insiders

0.07%

% Held by institutions

0.92%

Average volume (10 days)

1.21M

Average volume (90 days)

Price summary

52-Week low

8.54

52-Week high

28.80

52-Week change

-100.10%

Beta

1.23

50-Day moving average

10.37

200-Day moving average

14.28

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-283.19%

Operating margin

-256.55%

Operational effectiveness

Return on assets

-26.03%

Return on equity

-71.87%

Income statement

Revenue (ttm)

1.76

Revenue per share (ttm)

1.76

Quarterly revenue growth (yoy)

Gross profit (ttm)

53.03M

EBITDA

-223,552,992.00

Net income to common (ttm)

-238,804,992.00

Diluted EPS (ttm)

-5.01

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

255.46M

Total cash per share (mrq)

5.16

Total debt (mrq)

145.81M

Total Debt/Equity (mrq)

48.38

Current ratio (mrq)

305.10%

Book value per share (mrq)

6.08

Cash flow

Cash flow statement

-182,260,992.00

Levered free cash flow (LFCF)

-95,259,128.00